Background & Aims: Appearance of auto antibodies have been describedduring anti-tumor necrosis factor (TNF) alpha therapy; however, their prevalence andclinical relevance are still unclear. We investigated prevalence of autoantibodiesininflammatory bowel diseases (IBD) patients on anti-TNFα treatment and occurrence ofclinical symptoms.Methods: Titers of ANA, anti-dsDNA, SMA, AMA, LKM were evaluated from bloodsamples in patients receiving anti-TNFα inhibitor (adalimumab,infliximab).Results: Among 39 patients treated with anti-TNFα therapy, twenty of themdeveloped ANA, mostly induced by infliximab. 55% ANA positive patients developedperipheral polyarthralgias with no need for intervention. No patients with positiveautoantibodies developed a drug-induced lupus. The incidence of dsDNA, SMA andAMA was low and was not associated with autoimmune disease.Conclusions: Immune response induced by anti-TNFα is restricted to ANA, withlower prevalence of dsDNA antibodies, SMA and AMA. Further studies are needed toclarify the role of autoantibodies during anti-TNFα therapy.
|Numero di pagine||5|
|Rivista||JSM GASTROENTEROLOGY AND HEPATOLOGY|
|Stato di pubblicazione||Published - 2015|